Fremont, CA, United States of America

Fei Mao

This inventor holds 136 USPTO granted patents and 30 published patent applications, plus 6 CIPO patents and 15 EPO patents, primarily in Fluorescent Dyes (CPC class C12Q1-006). Top assignees: Abbott Diabetes Care Inc., Biotium, Inc., Therasense, Inc.. Active years: 1996-2026.

USPTO Granted Patents = 136 

% Patents Active = 56.6


 

Average Co-Inventor Count = 3.2

ph-index = 27

Forward Citations = 12,822(Granted Patents)

Forward Citations (Not Self Cited) = 12,007(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Eugene, OR (US) (1996 - 2005)
  • Fremont, CA (US) (2001 - 2023)

Company Filing History:


Years Active: 1996-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Fluorescent Dyes
Magnesium Compositions
Biosensor Membranes
Nucleic Acid Modifying Agents
Analyte Monitoring Devices
Redox Polymers
Heterocycle-Substituted Dyes
Enzyme Detection
Luminescent Metal Complexes
Small Volume Sensors
Protein Labeling Kits
Threonate Compounds
136 patents (USPTO):Explore Patents

Title: Fei Mao: An Innovative Mind Shaping the Future of Medicinal Compositions

Introduction:

Fei Mao, a renowned inventor and patent holder based in Fremont, CA, has made significant contributions to the field of medicinal compositions. With an impressive portfolio of patents and a strong career background, Mao has played a vital role in shaping advancements in healthcare. This article delves into his latest patents, career highlights, notable collaborations, and the impact of his contributions on the industry.

Latest Patents:

Mao's recent patents showcase his expertise in magnesium threonate compositions and their uses. In one of his groundbreaking inventions, Mao presents a dosage form that enhances the efficacy of magnesium threonate. These dosage forms and the associated pharmacokinetic profile have the potential to treat various diseases, disorders, syndromes, and conditions.

Another notable patent by Mao focuses on administering magnesium threonate to individuals in need of magnesium supplementation. The invention involves the use of a salt form of magnesium threonate, denoted as MgT, which may be administered at different time points during the day. Additionally, this patent explores the combination of multiple oral dosage forms, each exhibiting different dissolution profiles.

Career Highlights:

Fei Mao's career is marked by his involvement with prominent companies in the medical and pharmaceutical sectors. He has contributed his expertise to Abbott Diabetes Care Inc., a renowned innovator in glucose monitoring technologies and treatments. Additionally, Mao has collaborated with Biotium Inc., a company specializing in developing cutting-edge tools for biological research, diagnostic testing, and drug discovery.

Collaborations:

Throughout his career, Fei Mao has had the privilege of working alongside esteemed colleagues and inventors. Notably, he has collaborated with Adam Heller, a pioneer in electrochemical biosensors for diabetes management, and Benjamin J Feldman, an accomplished researcher specializing in pharmaceutical formulations and drug delivery systems. These collaborations have fostered an environment of knowledge exchange, leading to breakthrough innovations within the field.

Conclusion:

Fei Mao's remarkable contributions to the field of medicinal compositions position him as a leading force in the industry. With his extensive patent portfolio and involvement in prestigious companies, Mao continues to drive innovation in healthcare. By developing enhanced dosage forms and exploring novel ways to administer magnesium threonate, he provides promising solutions for the treatment of various conditions. Mao's notable collaborations further highlight his commitment to advancing the field through strategic partnerships. As his career progresses, we can expect to see more groundbreaking inventions from this visionary inventor.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…